Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein, secreted frizzled related protein 2 (SFFRP2), that is highly expressed in various solid cancers. Innova’s novel platform technology is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, triple negative breast cancer, multiple myeloma and pancreatic cancer. The opportunity for this anticancer therapy as a monotherapy and in combination with other chemotherapy agents will expand across other solid tumors. Osteosarcoma is a rare disease which was granted both orphan designation and rare pediatric disease designation from the FDA, which will expedite the regulatory approval timeline including the opportunity to obtain a Rare Pediatric Disease priority review voucher (value $100-120M). The program patent portfolio consists of 35+ patents ensuring global protection through 2040 and beyond.